Business Description
Imugene Ltd
ISIN : AU000000IMU9
Description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 61.15 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -71 | |||||
| 3-Year EPS without NRI Growth Rate | -71 | |||||
| 3-Year FCF Growth Rate | -58.7 | |||||
| 3-Year Book Growth Rate | 7.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.41 | |||||
| 9-Day RSI | 39.45 | |||||
| 14-Day RSI | 40.32 | |||||
| 6-1 Month Momentum % | -29.09 | |||||
| 12-1 Month Momentum % | -62.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.86 | |||||
| Quick Ratio | 3.86 | |||||
| Cash Ratio | 3.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.8 | |||||
| Shareholder Yield % | -18.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.32 | |||||
| ROA % | -77.57 | |||||
| ROIC % | -233.12 | |||||
| ROC (Joel Greenblatt) % | -1703.56 | |||||
| ROCE % | -85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.25 | |||||
| Price-to-Tangible-Book | 3.6 | |||||
| EV-to-EBIT | -1.24 | |||||
| EV-to-Forward-EBIT | -10.28 | |||||
| EV-to-EBITDA | -1.24 | |||||
| EV-to-Forward-EBITDA | -8.39 | |||||
| EV-to-FCF | -1.64 | |||||
| Price-to-Net-Current-Asset-Value | 3.6 | |||||
| Price-to-Net-Cash | 3.6 | |||||
| Earnings Yield (Greenblatt) % | -80.76 | |||||
| FCF Yield % | -42.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imugene Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.021 | ||
| Beta | 2.82 | ||
| Volatility % | 47.27 | ||
| 14-Day RSI | 40.32 | ||
| 14-Day ATR (A$) | 0.002179 | ||
| 20-Day SMA (A$) | 0.03835 | ||
| 12-1 Month Momentum % | -62.86 | ||
| 52-Week Range (A$) | 0.035 - 0.13 | ||
| Shares Outstanding (Mil) | 7,567.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imugene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imugene Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imugene Ltd Frequently Asked Questions
What is Imugene Ltd(ASX:IMU)'s stock price today?
The current price of ASX:IMU is A$0.04. The 52 week high of ASX:IMU is A$0.13 and 52 week low is A$0.04.
When is next earnings date of Imugene Ltd(ASX:IMU)?
The next earnings date of Imugene Ltd(ASX:IMU) is .
Does Imugene Ltd(ASX:IMU) pay dividends? If so, how much?
Imugene Ltd(ASX:IMU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers